Table 1 Comparisons of subject characteristics, clinical and laboratory data for baseline podocyturia marker sub-groups.
From: Podocyturia: an earlier biomarker of cardiovascular outcomes
Factor | Baseline podocin terciles (visit 1) | Baseline nephrin terciles (visit 1) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Low (n = 36) | Intermediate (n = 35) | High (n = 35) | Low (n = 36) | Intermediate (n = 35) | High (n = 35) | |||||||
Continuous | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD |
Age (years) | 47 | 8.2 | 45.6 | 10.0 | 46.9 | 8.6 | 46.4 | 8.1 | 46 | 9.7 | 47.1 | 9.0 |
BMI (kg/m2) | 27.8 | 2.90 | 27.9 | 3.4 | 28.2 | 2.7 | 28.2 | 2.7 | 27.9 | 3.6 | 27. 8 | 3.9 |
BSA (m2) | 1.98 | 0.13 | 1.97 | 0.22 | 1.87 | 0.26 | 1.99 | 0.13 | 1.94 | 0.23 | 1.9 | 0.26 |
SBP (mmHg) | 131 | 9 | 126 | 9 | 133 | 9b | 130 | 9 | 123 | 9 a | 136 | 7 a,b |
DBP (mmHg) | 70 | 8 | 66 | 7 | 71 | 6b | 69 | 7 | 66 | 8 | 72 | 6 b |
TG (mmol/l) | 2.0 | 0.7 | 1.5 | 0.6a | 1.4 | 0.4a | 1.9 | 0.7 | 1.6 | 0.7 | 1.4 | 0.5 a,b |
Total Cholesterol (mmol/l) | 6.9 | 1.3 | 8.1 | 8.0 | 6.7 | 1.4 | 7.3 | 1.2 | 7.6 | 0.8 | 6.9 | 1.4 |
HDL (mmol/l) | 1.09 | 0.37 | 1.11 | 0.39 | 0.97 | 0.30 | 1.13 | 0.36 | 1 | 0.41 | 1.04 | 0.28 |
LDL (mmol/l) | 3.7 | 0.7 | 3.4 | 0.6 | 3.2 | 0.7a | 3.7 | 0.7 | 3.3 | 0.7 | 3.4 | 0.6 |
HbA1C (%) | 7.4 | 0.5 | 7.2 | 0.5 | 7.4 | 0.5 | 7.3 | 0.5 | 7.2 | 0.5 | 7.5 | 0.4 b |
Serum creatinine (mmol/L) | 97 | 17 | 97 | 9 | 106 | 9b | 97 | 17 | 97 | 18 | 106 | 9 a,b |
Podocin mRNA (106 copies) | 0.39 | 0.07 | 0.68 | 0.13a | 1.27 | 0.17a,b | 0.45 | 0.11 | 0.68 | ± 0.28 a | 1.2 | 0.27 a,b |
Nephrin mRNA (106 copies) | 1.1 | 0.35 | 1.7 | 0.71a | 2.5 | 0.37a,b | 0.9 | 0.2 | 1.7 | ± 0.3 a | 2.6 | 0.2 a,b |
AER (mg/mmol) | 0.95 | 0.26 | 0.90 | 0.24 | 1.15 | 0.20b | 0.94 | 0.25 | 0.92 | 0.25 | 1.13 | 0.23 a,b |
Categorical | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Male | 12 | 33% | 16 | 46% | 18 | 51% | 14 | 39% | 14 | 40% | 18 | 51% |
Smoking | 31 | 86% | 32 | 91% | 29 | 83% | 32 | 89% | 29 | 83% | 31 | 89% |
Hypertension | 5 | 14% | 8 | 23% | 4 | 11% | 8 | 22% | 3 | 8.6% | 6 | 17% |
Oral hypoglycemics | 22 | 61% | 15 | 43% | 20 | 57% | 20 | 56% | 13 | 37% | 24 | 69% b |
Insulin | 31 | 86% | 29 | 83% | 30 | 86% | 33 | 92% | 27 | 77% | 30 | 86% |
ACE inhibitor | 11 | 31% | 8 | 23% | 16 | 46% | 12 | 33% | 5 | 14% | 18 | 51% b |
angiotensin receptor blocker | 10 | 28% | 4 | 11% | 7 | 20% | 7 | 19% | 4 | 11% | 10 | 29% |
Statin | 9 | 25% | 9 | 26% | 16 | 46% | 9 | 25% | 9 | 26% | 16 | 46% |
Outcomes at 7 years | ||||||||||||
Cerebrovascular disease | 1 | 3% | 19 | 54% a | 35 | 100% a,b | 2 | 5.6% | 21 | 60% | 34 | 97% b |
Coronary artery disease | 1 | 3% | 12 | 34% a | 26 | 74% a,b | 2 | 5.6% | 14 | 40% | 25 | 71% b |
Atrial fibrillation | 1 | 3% | 14 | 40% a | 23 | 66% a | 2 | 5.6% | 14 | 40% | 24 | 69% b |
Peripheral vascular disease | 1 | 3% | 9 | 26% a | 8 | 23% a | 2 | 5.6% | 7 | 20% | 11 | 31% |
